TriCalm Hydrogel® in the Treatment of Immunotherapy-Related Pruritus

Phase 2 Recruiting 28 enrolled University of California, San Diego

RandomizedParallel-groupOpen-labelSupportive care

Summary

This is a phase 2, randomized, open-label, single-center study that will assess the efficacy of TriCalm Hydrogel®, a topical gel containing strontium, for treating pruritus related to immune checkpoint inhibitors (ICIs).

Timeline

Start: 2025-03-05
Primary completion: 2027-12
Completion: 2028-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Aluminum Phosphate	Unknown	0.2 %	Topical
Comparator	Triamcinolone Acetonide	Other / unclassified	0.1 %	Topical

Indications

No indication recorded.